Decision

Abbvie Corporation v. Samsung Bioepis Co., Ltd., 2017 FC 675 (Adalimumab*)

Justice Manson - 2017-07-12

Read full decision. Automatically generated summary:

This is a motion on behalf of the Respondent, Samsung Bioepis Co., Ltd. (“Bioepis”), seeking a protective order regarding documents that will be disclosed pursuant to an underlying action, in which the Applicants, AbbVie Corporation and AbbVie Biotechnology Ltd. (together, “AbbVie”), are seeking orders prohibiting the Minster of Health from issuing notices of compliance pursuant to the Patented Medicines Notice of Compliance Regulations, SOR/93-133 [Regulations]. ... Since the purpose of the Proposed Prosecution Bar is different from the purpose of a CEO order, I find that the CEO test is not the appropriate test to determine whether the Proposed Prosecution Bar should be granted. I also find that Bioepis has not adduced sufficient evidence to show that the Proposed Prosecution Bar is necessary or reasonable in the context of this action.

Decision relates to:

  • T-598-17 - ABVIE CORPORATION ET AL v. SAMSUNG BIOEPIS CO. LTD. ET AL
  • T-599-17 - ABBVIE CORPORATION ET AL v. SAMSUNG BIOEPIS CO., LTD.ET AL
  • T-600-17 - ABBVIE CORPORATION ET AL
  • T-601-17 - ABBVIE CORPORATION ET AL v. SAMSUNG BIOEPIS CO LTD ET AL
  • T-602-17 - ABBVIE CORPORATION ET AL v. SAMSUNG BIOEPIS CO., LTD. ET AL
  • T-603-17 - ABBVIE CORPORATION ET AL v. SAMSUNG BIOEPIS CO., LTD. ET AL
  • T-604-17 - ABBVIE CORPORATION ET AL v. SAMSUNG BIOEPIS CO., LTD.ET AL
  • T-605-17 - ABBVIE CORPORATION ET AL v. SAMSUNG BIOEPIS CO., LTD.ET AL

 

Canadian Intellectual Property